If you run regulatory affairs for a product that files in both the US and EU, 2026 is a turning-point year. Three regulatory alignments landed in the same twelve-month window: QMSR took effect February 2, E2B(R3) becomes mandatory October 1, and the joint EMA-FDA AI principles formalised in January. Each cuts real cost. But convergence is partial. Variations still follow different logics, pharmacovigilance philosophies still differ, and the CHMP-to-European-Commission handoff still adds time. This post walks through what changed for dual-filing teams, what still costs you, and what mature RA organisations are doing differently in 2026.
What actually converged in 2026
Three items moved from "parallel systems with minor overlap" to "shared foundation." Every RA lead filing in both regions should have these baked into the 2026 plan.
1. FDA QMSR and ISO 13485: one medical device QMS, two regulators
The FDA QMSR took effect February 2, 2026. It replaces the US-specific language of 21 CFR Part 820 with direct incorporation of ISO 13485:2016 by reference, plus a small layer of US-specific requirements (labelling, records, UDI, complaint files).
What that means operationally: a medical device company with an ISO 13485 certified QMS now needs incremental FDA-specific overlay documentation, not a parallel quality system. The cost of maintaining dual QMS documentation that dominated the pre-QMSR era is structurally gone.
2. ICH E2B(R3): one pharmacovigilance data standard
From October 1, 2026, all postmarketing ICSRs submitted to FDA via ESG NextGen must use ICH E2B(R3). EMA's EudraVigilance has been on E2B(R3) since June 30, 2022. After October 1, a safety case file can be generated once and submitted to both authorities without a parallel E2B(R2) path.
For teams running dual safety databases, the vendor reconfiguration cost is front-loaded in 2026, but the ongoing operational cost drops permanently.
3. ICH E6(R3) and joint AI principles: one framework for clinical and AI
ICH E6(R3) is in force at EMA since July 23, 2025 and published as FDA final guidance on September 9, 2025. Clinical trial sponsors run a single RBQM framework that satisfies both regulators. On January 14, 2026, FDA and EMA jointly published 10 guiding principles for AI in drug development. The principles are voluntary but will underpin binding guidance in both jurisdictions.
For AI-dependent submissions, this means one governance package, not two.
Where divergence still costs you
Convergence is partial. Four persistent differences still drive cost on dual filings.
Variations classification remains split
A change that FDA treats as a CBE-30 can be Type IA, IB, or II at EMA. The mapping is not a rule; it is product- and change-specific. RA teams filing globally maintain a product-specific variation matrix mapping each change class across regulators, and validate each filing against both schemas. No convergence initiative has touched this in 2026.
| Change type | FDA category | Typical EMA category |
|---|---|---|
| Notification only | Annual Report | Type IA |
| Prior approval, minor | CBE-30 | Type IB |
| Prior approval, major | Prior Approval Supplement (PAS) | Type II |
| Labelling, safety | CBE-0 | Type IAIN or Type II |
Pharmacovigilance philosophies still diverge
Both agencies now share the same data format, but the operating philosophy differs. FDA leans on benefit-risk labelling and REMS before market withdrawal. EMA's PRAC applies a more precautionary standard, with suspension more frequent when safer alternatives exist. A product under active safety review in both regions can face parallel regulatory trajectories.
Decision authority adds time in the EU
FDA reaches a final approval decision itself. EMA issues a CHMP opinion; the European Commission issues the binding marketing authorisation decision. That handoff adds weeks to the end-to-end EU timeline that a "210 days" headline does not show.
Expedited programs map imperfectly
FDA Breakthrough Therapy Designation has no direct EMA equivalent; the closest is PRIME, which differs in scope and interaction cadence. Dual expedited status requires separate applications and separate scientific engagement tracks.
What mature RA teams do differently in 2026
Three operating patterns show up repeatedly in teams that run dual filings efficiently.
Single-source authoring, regional finishing. Clinical protocols, M2-M5 of eCTD, safety documents, QMS SOPs authored once against ICH or ISO baseline. FDA-specific and EU-specific overlays applied at the finishing stage. This was hard pre-QMSR; after February 2, 2026, it is the default pattern for device teams and is practical for drug teams with ICH-harmonised documents.
Product-specific divergence matrix. A single document per product listing every known US-EU difference that applies: variations categorisation, labelling differences, pharmacovigilance commitments, safety reporting quirks, expedited status. Updated when any of the four items changes. This document survives team turnover and is the audit-ready artefact.
Parallel scientific engagement, not sequential. Teams that sequence FDA first, EMA later (or vice versa) pay a timeline penalty. Running scientific advice in parallel at both agencies costs twice up front and saves 6-12 months at the end.
Integrated safety reporting. After October 1, 2026, a single safety case generation workflow feeds both FAERS/AEMS and EudraVigilance. Teams still running two parallel safety configurations are carrying dead cost.
Planning rhythm for 2026
The practical implication for a 2026 plan: identify where your organisation is still running parallel systems that 2026 alignment has retired, and retire them. Common targets:
- Dual QMS documentation sets (retire to single ISO 13485 + US overlay)
- Parallel E2B(R2) and E2B(R3) safety submission paths (retire to E2B(R3) only once ready)
- Dual RBQM frameworks for clinical trials (retire to ICH E6(R3) plus jurisdiction-specific addenda)
- Separate AI governance documents for FDA and EMA filings (retire to one document structured against the 10 joint principles)
The cost recovery is structural, not a one-time saving. The teams that make these moves first will be better positioned for the next wave of alignment (eCTD v4.0 mandatory in EU for CAPs in 2026, and the continuing ICH M14 and E2D revisions in the pipeline).
Key takeaways
- 2026 brought three operational convergences (QMSR + ISO 13485, E2B(R3), ICH E6(R3) + joint AI principles) that remove structural cost from dual filings
- Variations remain split, pharmacovigilance philosophies remain different, and the EU CHMP-to-EC handoff still adds time
- Mature RA teams author centrally and finish regionally, maintain a product-specific divergence matrix, run scientific advice in parallel, and unify safety reporting
- The 2026 plan should audit parallel systems that are now redundant and retire them
How RegAid helps
RegAid tracks the convergence moves and the divergence points in one cited search layer covering FDA, EMA, MDCG, Swissmedic, ICH, eCFR, EUR-Lex, and agency gazettes. When you need to answer "does this product change count as CBE-30 at FDA and Type IB at EMA?" or "what did the joint AI principles change for our pharmacovigilance models?", ask RegAid, get a cited answer in seconds, and keep your divergence matrix current without the manual research loop.